Navigation Links
Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
Date:3/29/2011

SAN DIEGO, March 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5.

ACC:  Ernest N. Morial Convention Center (Expo Hall), New Orleans, LA.  Sunday, April 3:  Poster PresentationAbstract: 286Presenter: Jorge Plutzky, MD, Director, Vascular Disease Prevention Program, Brigham and Women's Hospital, Boston, MATitle: "Weight Loss, Blood Pressure, Pulse and Circadian Patterns with Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy for Obesity"Time: 10:00 – 11:15 a.m. CDTLocation: Hall FSession Title: Risk Reduction and Rehabilitation:  Role of Exercise IIAbout Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen® Therapeutics Announces Corporate Realignment
2. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
3. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
4. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
5. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
6. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
7. Northwest Biotherapeutics Addresses Recent Market Activity
8. MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
9. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
10. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
11. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... company, today announced several positive developments that position the Company for the future. ... of the transaction, Craig F. Kinghorn has been appointed Chairman of the Board, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice ... surgery and surgery of the hand by the National Board of Physicians and ... above and beyond in his pursuit of providing the most comprehensive, effective treatment ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug designation ... company’s second orphan drug designation granted by the FDA. , Spinocerebellar ataxia ...
(Date:5/23/2016)... , ... May 23, 2016 , ... The need for blood donations in South Texas ... by the South Texas Blood & Tissue Center, blood donations are on the decline. In ... and they are down 21 percent in South Texas in the last four years alone. ...
Breaking Biology Technology:
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... --> --> ... and Access Management Market by Component (Provisioning, Directory Services, ... Organization Size, by Deployment, by Vertical, and by Region ... market is estimated to grow from USD 7.20 Billion ... a Compound Annual Growth Rate (CAGR) of 12.2% during ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):